Open AccessGene polymorphisms in chronic C virus hepatitis
Author(s) -
Klára Werling,
Kàroly Rácz
Publication year - 2012
Publication title -
interventional medicine and applied science/interventional medicine and applied science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.195
H-Index - 14
eISSN - 2061-5094
pISSN - 2061-1617
DOI - 10.1556/imas.4.2012.2.2
Subject(s) - ribavirin , genotyping , medicine , hepatitis c virus , genotype , pegylated interferon , virology , hepatitis c , immunology , interleukin 28b , viral load , virus , gene , genetics , biology
The hepatitis C virus (HCV) is a major public health problem in the world. Current standard of treatment with pegylated interferonalpha (PegIFN) and ribavirin (RBV) achieves a sustained virological response in 40–50% of those infected with genotype 1. Host genotyping studies have the potential to identify genes and therefore pathogenic processes important in viral clearance, enabling a rational approach to design new drugs, and to identify patients who will most likely respond to current and new treatments. The polymorphisms in IL28B are highly predictive of response to PegIFN and RBV combination therapy for HCV genotype 1 infection. Possibly combined to other baseline features, such as the measurements of IP-10 and HLA-C as well as on-treatment viral kinetics, should allow for improved prediction of response to HCV combination therapy. Host genetics have significant role in spontaneous clearance of HCV. Genotyping of this polymorphism will aid clinical decision making for both current standard of care and potentially for the integration of other agents in the future, providing an opportunity for clinicians to individualize treatment regimens for hepatitis C patients.